McAuley James W, Anderson Gail D
The Ohio State University College of Pharmacy, 500 West 12th Avenue, Columbus, OH 43210, USA.
Clin Pharmacokinet. 2002;41(8):559-79. doi: 10.2165/00003088-200241080-00002.
Although epilepsy affects men and women equally, there are many women's health issues in epilepsy, especially for women of childbearing age. These issues, which include menstrual cycle influences on seizure activity (catamenial epilepsy), interactions of contraceptives with antiepileptic drugs (AEDs), pharmacokinetic changes during pregnancy, teratogenicity and the safety of breastfeeding, challenge both the woman with epilepsy and the many healthcare providers involved in her care. Although the information in the literature on women's issues in epilepsy has grown steeply in recent years, there are many examples showing that much work is yet to be done. The purpose of this article is to review these issues and describe practical considerations for women of childbearing age with epilepsy. The article addresses the established or "first-generation" AEDs (phenobarbital, phenytoin, primidone, carbamazepine, ethosuximide and valproic acid) and the "second-generation" AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide). Although a relationship between hormones and seizure activity is present in many women, good treatment options for catamenial epilepsy remain elusive. Drug interactions between enzyme-inducing AEDs and contraceptives are well documented. Higher dosages of oral contraceptives or a second contraceptive method are suggested if women use an enzyme-inducing AED. Planned pregnancy and counselling before conception is crucial. This counselling should include, but is not limited to, folic acid supplementation, medication adherence, the risk of teratogenicity and the importance of prenatal care. AED dosage adjustments may be necessary during pregnancy and should be based on clinical symptoms, not entirely on serum drug concentrations. Many groups have turned their attention to women's issues in epilepsy and have developed clinical practice guidelines. Although the future holds promise in this area, many questions and the need for progress remain.
虽然癫痫对男性和女性的影响相同,但癫痫存在许多女性健康问题,尤其是育龄女性。这些问题包括月经周期对癫痫发作活动的影响(经期性癫痫)、避孕药与抗癫痫药物(AEDs)的相互作用、孕期药代动力学变化、致畸性以及母乳喂养的安全性,这些问题给患有癫痫的女性以及参与其护理的众多医疗服务提供者都带来了挑战。尽管近年来关于癫痫女性问题的文献资料急剧增加,但有许多例子表明仍有许多工作有待完成。本文的目的是回顾这些问题,并描述针对育龄癫痫女性的实际注意事项。本文讨论了已有的或“第一代”抗癫痫药物(苯巴比妥、苯妥英、扑米酮、卡马西平、乙琥胺和丙戊酸)以及“第二代”抗癫痫药物(非氨酯、加巴喷丁、拉莫三嗪、左乙拉西坦、奥卡西平、替加宾、托吡酯、氨己烯酸和唑尼沙胺)。虽然许多女性体内存在激素与癫痫发作活动之间的关系,但经期性癫痫的良好治疗方案仍然难以捉摸。酶诱导性抗癫痫药物与避孕药之间的药物相互作用已有充分记录。如果女性使用酶诱导性抗癫痫药物,建议增加口服避孕药的剂量或采用第二种避孕方法。计划怀孕并在受孕前进行咨询至关重要。这种咨询应包括但不限于补充叶酸、坚持用药、致畸风险以及产前护理的重要性。孕期可能需要调整抗癫痫药物的剂量,且应基于临床症状,而不完全基于血清药物浓度。许多团体已将注意力转向癫痫女性问题,并制定了临床实践指南。尽管该领域未来充满希望,但仍有许多问题以及取得进展的需求。